Interesting Images

¹⁸F-FDG PET/CT Metabolic Response With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors

Filizoglu, Nuh MD; Ozguven, Salih MD; Erdil, Tanju Yusuf MD

From the Department of Nuclear Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey.

Received for publication January 25, 2022; revision accepted February 3, 2022.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Nuh Filizoglu, MD, Department of Nuclear Medicine, Marmara University Pendik Training and Research Hospital, Fevzi Cakmak District Muhsin Yazıcıoglu Street No:10, 34899 Pendik, Istanbul, Turkey. E-mail: [email protected].

Clinical Nuclear Medicine 47(9):p e605-e606, September 2022. | DOI: 10.1097/RLU.0000000000004177

Abstract

Dysregulation of the cyclin D–CDK4/6–INK4–RB pathway, which leads to uncontrolled cell proliferation, is frequently observed in breast cancer. Recently, 3 CDK4/6 inhibitors have been FDA approved as first-line treatment for patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Despite promising clinical results, the metabolic response to treatment with these new drugs has not been elaborately demonstrated yet. Herein, we presented a patient with hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer who demonstrated a complete metabolic response on ¹⁸F-FDG PET/CT to treatment with a CDK4/6 inhibitor (ribociclib).